Prognostic impact of vasopressor test in transcatheter edge‐to‐edge repair of secondary mitral regurgitation: The PETIT study

Background Vasopressor test (VPT) might be useful in patients with functional mitral regurgitation (MR) and left ventricular dysfunction (MITRA‐FR‐like patients) during transcatheter edge‐to‐edge repair (TEER). Aims We aimed to evaluate the prognostic impact of VPT. Methods MR treated with TEER were...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 104; no. 2; pp. 378 - 389
Main Authors González‐Gutiérrez, José Carlos, Benito‐González, Tomas, Bosa‐Ojeda, Francisco, Freixa‐Rofastes, Xavier, Estevez‐Loureiro, Rodrigo, Pascual, Isaac, Andraka‐Ikazuriaga, Leire, Díez‐Gil, José Luis, Urbano‐Carrillo, Cristobal, Amat‐Santos, Ignacio J.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.08.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Vasopressor test (VPT) might be useful in patients with functional mitral regurgitation (MR) and left ventricular dysfunction (MITRA‐FR‐like patients) during transcatheter edge‐to‐edge repair (TEER). Aims We aimed to evaluate the prognostic impact of VPT. Methods MR treated with TEER were included in a multicenter prospective registry. VPT was used intraprocedurally in patients with left ventricular dysfunction and/or hypotension. The 1‐year echocardiographic and clinical outcomes were compared according to the use of VPT. The primary endpoint was a combination of mortality + heart failure (HF) readmission at 1‐year. Results A total of 1115 patients were included, mean age was 72.8 ± 10.5 years and 30.4% were women. VPT was performed in 128 subjects (11.5%), more often in critically ill patients with biventricular dysfunction. Postprocedurally the VPT group had greater rate of MR ≥ 2+ (46.9% vs. 31.7%, p = 0.003) despite greater number of devices (≥2 clips, 52% vs. 40.6 p = 0.008) and device repositioning or new clip in 12.5%. At 1‐year, the primary endpoint occurred more often in the VPT group (27.3% vs. 16.9%, p = 0.002) as well as all‐cause mortality (21.9% vs. 8.1%, p ≤ 0.001) but no differences existed in HF readmission rate (14.8% vs. 13.2%, p = 0.610), cardiovascular mortality (4.4% vs. 3.9%, p = 0.713) or residual MR ≥ 2+ (51.1% vs 51.7%, p = 0.371). Conclusions Dynamic evaluation of MR during TEER procedure through VPT was performed in patients with worse baseline risk who also presented higher all‐cause mortality at 1‐year follow‐up. However, 1‐year residual MR, cardiovascular mortality and HF readmission rate remained comparable suggesting that VPT might help in the management of MITRA‐FR‐like patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1522-1946
1522-726X
1522-726X
DOI:10.1002/ccd.31115